Cargando…
In vitro and in vivo studies of plant-produced Atezolizumab as a potential immunotherapeutic antibody
Immune checkpoint inhibitors are a well-known class of immunotherapeutic drugs that have been used for effective treatment of several cancers. Atezolizumab (Tecentriq) was the first antibody to target immune checkpoint PD-L1 and is now among the most commonly used anticancer therapies. However, this...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465495/ https://www.ncbi.nlm.nih.gov/pubmed/37644118 http://dx.doi.org/10.1038/s41598-023-41510-w |